There is limited immunity at best. We think so because survived patients’ serum can be used with modest success in a newly infected patient. However, there have not been enough trials of antibody therapy to make a definite statement on this.
“We think so because survived patients’ serum can be used with modest success in a newly infected patient. However, there have not been enough trials of antibody therapy to make a definite statement on this.”
This is something that should certainly be researched.